Recruiting

Quality of Life

Sponsor:

Children's Hospital of Philadelphia

Code:

NCT07950878

Conditions

ARPKD

Eligibility Criteria

Sex: All

Age: 0 - 25

Healthy Volunteers: Accepted

Interventions

Questionnaires

Study Details

Brief summary:

Chronic kidney disease (CKD) in childhood is a significant burden and reduces the quality of life for both children and their parents. CKD is especially burdensome when it progresses to end stage kidney disease (ESKD, previously referred to as end-stage renal disease or ESRD), placing considerable demands on a childs entire family. Although studies are available for all-cause CKD and for some disease subsets, there is no study capturing quality of life in children or adolescents specifically affected by autosomal recessive polycystic kidney disease (ARPKD). These children are often severely affected prenatally and postnatally have problems due to massive kidney enlargement, hypertension, kidney failure, and portal hypertension. They often need to receive kidney replacement therapy during childhood.

The need to include patients and their lived experience in the design of clinical trials exists for all diseases, but is implemented infrequently, especially in the field of rare diseases. The negative consequences of limited patient/parent input in clinical trial design for rare diseases has been recently highlighted by a report from the International Rare Diseases Research Consortium (IRDiRC).

Conditions

ARPKD

Study ID

NCT07950878

Start date

Nov 6, 2024

Status verified date

Nov, 2026

Completion date

Nov 6, 2030

Anticipated

Primary completion date

Nov 6, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0 - 25

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Subjects should be over 18 years of age and permanently live in the same household as the child/ young person with ARPKD.

Exclusion Criteria:

  • Insufficient understanding of the questions due to intellectual capabilities or language barriers. However, translation by a professional interpreter is permissible.

Lack of written informed consent. Subjects that choose not to have their responses recorded.

Study Design

Enrollment

40 participants

Anticipated

Interventions and Outcome Measures

Arms

Patients with ARPKD and their caregivers

Interventions

Questionnaires

Families will be asked to fill out a series of questionnaires

Primary outcome measure

  • PedsQL ESRD Questionnaire [ Time Frame: 5 years ]
  • SDQ (strength and difficulties questionnaire) [ Time Frame: 5 years ]
  • IFS (impact on family scale) [ Time Frame: 5 years ]
  • ULQIE (Ulm Quality of Life Inventory for Parents of Chronically Ill Children) [ Time Frame: 5 years ]

Central Contacts and Locations

Central contacts

Locations

Children's Hospital of Philadelphia

Recruiting

Philadelphia, Pennsylvania, United States, 19146

Contacts

Principal Investigator:

Lisa Guay-Woodford, M.D.

More Information

Sponsor

Children's Hospital of Philadelphia

Last update posted

Nov 20, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-21. This information was provided to ClinicalTrials.gov by Children's Hospital of Philadelphia on 2026-11-20. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.